Pregene Biopharma
The ESO-T01 Phase 1 publication includes a Pregene-affiliated coauthor alongside EsoBiotec. This establishes participation in the published work, not independent ownership of ESO-T01 or a separate verified in vivo CAR-T pipeline. Commercial rights require further confirmation.
Corporate information
- Company entity
- Pregene Biopharma
- Headquarters / principal office
- Shenzhen, China ↗
- Founded
- 2012 ↗
- Ownership / capital status
- PrivateSeries B (historical company disclosure) ↗
- Official corporate reference
- https://www.pregene.com/ ↗
- Latest financing / award identified
- 2020-09 · Series B · CNY 140 million ↗
- LinkedIn company page
- Independent company page not verified
Company history gives September 2020 only; no day is inferred. This historical financing is not confirmed as the latest. IPO plans do not establish a completed listing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
The ESO-T01 Phase 1 publication includes a Pregene-affiliated coauthor alongside EsoBiotec. This establishes participation in the published work, not independent ownership of ESO-T01 or a separate verified in vivo CAR-T pipeline. Commercial rights require further confirmation.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Pregene Biopharma — primary program / ownership disclosure
- Pregene Biopharma — supporting primary disclosure
- Primary corporate profile / legal-entity disclosure
- Pregene official corporate history and financing timeline